Summary by Moomoo AI
Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced an amendment to its tender offer to acquire all outstanding shares of Alpine Immune Sciences, Inc. The offer, initially filed with the SEC on April 22, 2024, proposes a purchase price of $65.00 per share in cash. The tender offer is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. A key condition of the offer, the expiration of the waiting period under the HSR Act, was met on May 9, 2024, as both Vertex and Alpine filed their respective HSR Notification Forms with the FTC and the DOJ. The successful completion of this waiting period satisfies one of the conditions for the offer's consummation. The terms and conditions of the offer are detailed in the Offer to Purchase and the accompanying Letter of Transmittal, which are filed with the SEC. The amendment was signed by Jonathan Biller, Secretary of Adams Merger Sub, Inc., and Executive Vice President and Chief Legal Officer of Vertex Pharmaceuticals Incorporated, on May 10, 2024.